Q-omics provides the consensus-scored TRPC7 profile across patient tissues and cancer cell-line models. TRPC7 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TRPC7 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, TRPC7 RNA expression shows 10,779 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where TRPC7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRPC7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRPC7 survival associations across molecular data types. TRPC7 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRPC7 RNA expression–survival associations across cancer types. High TRPC7 expression shows unfavorable associations in BRCA, SCLC, UCEC and MESO, but favorable associations in KIRC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TRPC7 RNA expression.
This table summarizes TRPC7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRPC7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRPC7 shows lower tumor expression in COAD, KICH, KIRC and READ and higher tumor expression in THCA and LUSC. The COAD box plot shows higher TRPC7 RNA expression in normal versus tumor tissue (log2 FC = −0.399, t-test p < 0.001).
This table shows molecular features associated with TRPC7 in patient tissues and cancer cell lines. In patient samples, TRPC7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TRPC7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
